Dr. Galasko is a clinician-researcher who focuses on Alzheimer’s Disease, Parkinson’s Disease and other disorders resulting in cognitive impairment and dementia. He currently serves as Director of the UCSD Shiley-Marcos Alzheimer's Disease Research Center (ADRC). He is a member of the Alzheimer’s Disease Cooperative Study, a NIH-funded consortium of medical Centers that conducts clinical trials in Alzheimer’s Disease.
In clinical practice, he provides expert evaluation and comprehensive care for patients with memory and cognitive disorders, including Alzheimer’s Disease, Frontotemporal Dementia, Progressive Aphasia, and Dementia with Lewy Bodies, at the UCSD Perlman Neurology Clinic.
He also is a Staff Physician in the Neurology Service of the VA Medical Center, La Jolla, where he sees patients with a variety of neurological disorders.
Dr. Galasko has made significant original research contributions in the area of Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and other disorders associated with cognitive impairment and dementia. He has authored 250 journal articles, over 30 book chapters, and serves as Co-Editor of the journal Alzheimer’s Research and Therapy. He has served on committees to develop diagnostic criteria for Dementia with Lewy Bodies and to standardize biological sample collection for multicenter research studies.
He has received research funding from the National Institute on Aging, the State of California, the Alzheimer Association, the Michael J Fox Foundation and the Alzheimer’s Disease Drug Discovery Foundation. He also has conducted clinical trials with funding from Pfizer, Elan, and Eli Lilly, Inc.
He serves as a grant reviewer for the National Institutes of Health, the Veterans Administration, and Foundations that include the Michael J Fox Foundation, the Bright Focus Foundation, and the American Federation for Aging Research. He serves on advisory boards for academic research groups and pharmaceutical companies.
Nation DA, Edland SD, Bondi MW, Salmon DP, Delano-Wood L, Peskind ER, Quinn JF, Galasko DR. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology. 2013 Nov 13.
Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of Knowledge of APOE Genotype on Subjective and Objective Memory Performance in Healthy Older Adults. Am J Psychiatry. 2013. doi: 10.1176/appi.ajp.2013.12121590.
Wang LY, Murphy RR, Hanscom B, Li G, Millard SP, Petrie EC, Galasko DR, Sikkema C, Raskind MA, Wilkinson CW, Peskind ER. Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span. Neurobiol Aging. 2013.
Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J. Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med. 2012;4(121):121ra20
Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, 229. Bennett DA, Arnold SE, Harold D, Sims R, Gerrish A, Williams J, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Peskind ER, Galasko D, Fagan AM, Holtzman DM, Morris JC; GERAD Consortium; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC), Goate AM. GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease. Neuron. 2013;78:256-68.
Wagner SL, Tanzi RE, Mobley WC, Galasko D. Potential Use of γ-Secretase Modulators in the Treatment of Alzheimer Disease. Arch Neurol. 2012 Jul 16:1-4.
Galasko D, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P, for the Alzheimer’s Disease Cooperative Study. Antioxidants for Alzheimer’s Disease: a randomized clinical trial with CSF biomarker measures. Archives of Neurology, 2012
See more at PubMed